TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07331155: An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 03(ESCC)]

Sponsor: Nanjing Leads Biolabs Co.,Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 110 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,739,600

Rescue Site Savings

+$4,448,800

Unlock Full NCT07331155 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07331155 Rescue Dossier →